Abstract library

17 results for "Álvarez".
#241 One-year Response to Everolimus in a Case of Advanced Pancreatic NET
Introduction: A stage IV pancreatic NET (30 mitoses/10 PF and Ki-67 index=40%) with liver and peritoneal metastases was diagnosed in a 35-year-old woman in June 2008. Characteristics: ECOG2 and CgA 1701 ng/ml.
Conference: 8th Annual ENETS Conference (2011)
Category: Clinical
Presenting Author: MD Paula Jiménez Fonseca
#257 Doxorubicin, Etoposide and Cisplatin as first-line Treatment in Advanced Adrenocortical Carcinoma
Introduction: Adrenocortical carcinoma (ACC) is a rare cancer with poor prognosis in advanced setting due to its low chemosensibility. Mitotane and cisplatin-based regimens are the most frequently used treatments.
Conference: 8th Annual ENETS Conference (2011)
Category: Clinical
Presenting Author: MD Paula Jiménez Fonseca
#460 Treatment of Unresectable Metastatic GEP NETs: Data From a Prospective Observational Unicentric Study
Introduction: In 2010 Everolimus, Sunitinib and Capecitabine plus Temozolamide confirmed efficacy in NETs.
Conference: 9th Annual ENETS Conference (2012)
Category: Clinical
Presenting Author: MD Paula J Fonseca
#544 Second Primary Tumor in Patients with Gastroenteropancreatic Neuroendocrine Tumors (GEPNETs): Data From a Retrospective Observational Unicentric Study
Introduction: It is known that GEPNETs are associated with a high incidence of second primary tumors, especially in the context of inherited syndromes and synchronous injuries to the intestine.
Conference: 9th Annual ENETS Conference (2012)
Category: Clinical
Presenting Author: MD Paula J Fonseca
#639 Clinical Features and Treatment of GEP NETs in a Spanish Hospital Through 8 Years
Introduction: There are discrepancies in Gastroenteropancreatic NETs (GEPNET) incidence, characteristics and patterns of care among institutional registries and countries.
Conference: 10th Annual ENETS Conference (2013)
Category: Epidemiology/Natural history/Prognosis - Registries, nationwide and regional surveys
Presenting Author: Msc MD María del Pilar Solis
#641 Metastatic Gastroenteropancreatic Neuroendocrine Tumors (GEP NETs) Management in a Spanish University Hospital
Introduction: GEP-NETs are malignant entities poorly understood still, deserving important attention for a better management of the disease.
Conference: 10th Annual ENETS Conference (2013)
Category: Medical treatment – Chemotherapy, medical treatment - others
Presenting Author: Msc MD María Del Pilar Solis-Hernandez
#642 Correlation Between Chromogranin A and RECIST in Neuroendocrine Tumors’ Treatment
Introduction: High Chromogranin A (CGA) levels have been associated with both tumor burden and the secretory activity of GEPNETs specially carcinoids.
Conference: 10th Annual ENETS Conference (2013)
Category: Biomarkers
Presenting Author: PhD MD Paula Jimenez Fonseca
#882 Gene Expression Characterization of Gastroenteropancreatic Neuroendocrine Tumors [GEPNETS: Gastrointestinal and Pancreatic NETs (GINETs and pNETs)] and Their Correlation with Clinical Factors and Tumor Behavior
Introduction: GEP-NETs are a heterogenous group of tumors with different molecular backgrounds and clinical outcome.
Conference: 11th Annual ENETS Conference (2014)
Category: Basic Science - Genetics, epigenetics, miRNAs
Presenting Author: J A Díaz Pérez
#966 Evaluation of Lysyl Oxidase-Like-2 (LOXL2) Expression by Immunohistochemistry (IHC) in Gastroenteropancreatic Neuroendocrine Tumors (GEP-NET): A Retrospective Analysis and Comparison with PTEN
Introduction: A better understanding of the relationship between the stroma and the cancer cells of this group of malignancies remains a challenge. LOXL2 is an enzyme that contributes to the synthesis and stabilization of the cellular matrix and plays a role in angiogenesis.
Conference: 11th Annual ENETS Conference (2014)
Category: Biomarkers
Presenting Author: Dr Jorge Barriuso
Keywords: LOXL2, GEP-NET
#1153 Prognostic Role of Diabetes Mellitus (DM) and Metformin (MET) Therapy in Patients (pts) with Advanced G1-G2 Neuroendocrine Tumors (NETs) Treated with Everolimus (EVE)
Introduction: MET has shown antitumorigenic effects on DM cancer pts, which are mediated by decrease of insulin/IGF-1 levels and activation of the AMPK pathway leading to mTOR inactivation.
Conference: 12th Annual ENETS Conference (2015)
Category: Medical treatment - Targeted therapies
Presenting Author: MD Ana Custodio
Close
Notice

WARNING – FRAUDULENT WEBSITES

ENETS is aware that its members have been confronted with fake websites, which seem to relate to our congress but have not been commissioned or authorised by us. The websites offer fraudulent hotel reservation services. We therefore strongly recommend that you please only use the official enetsconference.org website when booking your tickets and accommodation. Please be vigilant when it comes to providing your credit card details. 

If you have any questions, please do not hesitate to contact us at info@enets.org.